Massachusetts Alzheimer's Disease Research Center

马萨诸塞州阿尔茨海默病研究中心

• 批准号: 10332246
• 负责人: BRADLEY T. HYMAN
• 金额: $ 5.94万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-15 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10332246
• 关键词: Alzheimer' s Disease; Amyloid beta-Protein; Authorization documentation; Autopsy; Basic Science; Behavioral; Biological Assay; Biological Markers; Blood; Blood Vessels; Cerebrospinal Fluid; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Design; Cognitive; Collaborations; Communities; Data; Data Linkages; Data Set; Dementia; Development; Diagnosis; Diagnostic Services; Disease; Education; Environment; Event; Faculty; Faculty Recruitment; Fertilization; Frontotemporal Dementia; Functional disorder; Future; General Hospitals; Goals; Heterogeneity; Image; Imaging Techniques; Impairment; Individual; Infrastructure; Institution; Knowledge; Laboratories; Leadership; Learning; Lesion; Lewy Body Disease; Link; MRI Scans; Marshal; Massachusetts; Measures; Mentors; Methods; Mission; Molecular Profiling; Natural Immunity; Nerve Degeneration; Neurofibrillary Tangles; Neuropsychology; Participant; Pathology; Patients; Phenotype; Plasma; Play; Population Heterogeneity; Positron-Emission Tomography; Process; Prognosis; Research; Research Methodology; Research Personnel; Research Support; Resources; Role; Sampling; Science; Scientist; Statistical Data Interpretation; Structure; Techniques; Technology; Testing; Therapeutic Trials; Training; Training Programs; Update; Work; base; biomarker validation; clinical biomarkers; clinical center; clinical phenotype; cohort; community setting; digital; disease heterogeneity; education research; follow-up; frontotemporal degeneration; imaging biomarker; imaging study; induced pluripotent stem cell; inflammatory marker; inter-individual variation; medical schools; mild cognitive impairment; multidisciplinary; neuroimaging; neuropathology; new technology; next generation; outreach; posters; programs; racial and ethnic; recruit; resilience; symposium; targeted biomarker; tau Proteins; therapeutic evaluation; therapeutic target; tool; validation studies

OVERVIEW: Massachusetts Alzheimer’s Disease Research Center (MADRC) The MADRC is an interdisciplinary Center at Massachusetts General Hospital, Harvard Medical School, with two major strategic goals: 1) to understand the underpinnings of heterogeneity of Alzheimer’s disease and Alzheimer’s Disease Related Disorders, and 2) to develop techniques, strategies, and technologies to accelerate a cure. To approach these goals, we propose 7 Cores (Administrative, Clinical, Biomarker, Imaging, Neuropathology, Data, and Outreach). We will use advanced Imaging, Biomarker, and analytic approaches to study our Research Cohort, which we view as a state of the art clinical phenotyping laboratory. Autopsy follow up for validation of biomarkers and imaging, and therapeutic targets, is essential. We plan to study a diverse population, both in the sense of various pathophysiologies, and also with varying racial and ethnic backgrounds, and rely on a vigorous ORE core both to fulfill our own recruitment needs and to support clinical trials and other affiliated programs. We have refocused our Center’s activities by remodeling the Research Cohort to include subjects who are cognitively normal, have mild cognitive impairment, or dementia, targeting diverse causes of dementia including Alzheimer’s disease and related disorders (Frontotemporal dementia, Lewy Body Disease, and vascular lesions). We postulate that heterogeneity of progression, even among individuals with the same “disease”, reflects underlying differences that can be uncovered, and that doing so will enhance clinical trial design by parsing variability from the very large, long cohort trials now in common use. Each Core is challenged to develop tools to help accelerate a cure – from intermediate imaging/biomarker targets that may help with diagnosis (a patient’s state) or prognosis (a patient’s fate), to performing autopsies to validate those targets. We will develop markers of inflammation and neurodegeneration, believing that innate immunity and resilience play a role in addition to tangles and plaques. Development of statistical and data methods are critical for anlaysis. These tools will allow us to test hypotheses about faster or slower rates of progression in a deeply phenotyped cohort. A final goal, central to our mission, is to build the future by training the next generation of scientists, which we propose to do under the framework of the Research Education Component. Together, we hope to make a difference in these devastating diseases.

马萨诸塞州阿尔茨海默病研究中心（MADRC） MADRC是哈佛医学院马萨诸塞州总医院的一个跨学科中心， 两个主要战略目标：1）了解阿尔茨海默病异质性的基础， 阿尔茨海默病相关疾病，2）开发技术，策略和技术， 加速治愈为了实现这些目标，我们提出了7个核心（管理，临床，生物标志物， 影像学、神经病理学、数据和外展）。我们将使用先进的成像、生物标记和分析技术， 研究我们的研究队列的方法，我们认为这是一个最先进的临床表型实验室。 尸检后续验证的生物标志物和成像，和治疗目标，是必不可少的。我们计划 研究不同的人群，无论是在各种病理生理学的意义上，也与不同的种族和 种族背景，并依赖于一个充满活力的ORE核心，以满足我们自己的招聘需求，并支持 临床试验和其他附属项目。 我们重新调整了我们中心的活动，重塑了研究队列，纳入了以下受试者： 认知正常，有轻度认知障碍或痴呆，针对痴呆的各种原因 包括阿尔茨海默病和相关病症（额颞叶痴呆、路易体病和阿尔茨海默病）。 血管病变）。我们假设，即使在具有相同特征的个体之间， “疾病”，反映了潜在的差异，可以发现，这样做将提高临床试验 通过分析目前常用的大型、长期队列试验的变异性进行设计。 每个核心都面临着开发工具以帮助加速治愈的挑战-从中间成像/生物标志物 从有助于诊断（病人的状态）或预后（病人的命运）的目标，到进行尸检 来验证这些目标我们将开发炎症和神经变性的标志物，相信， 除了缠结和斑块之外，先天免疫和恢复力也起作用。发展统计和 数据方法是分析的关键。这些工具将使我们能够测试关于更快或更慢速率的假设 在深度表型化的队列中的进展。 最后一个目标，也是我们使命的核心，是通过培养下一代科学家来建设未来， 建议在研究教育组成部分的框架下进行。我们一起希望 这些致命疾病的区别。